Recombinant Mycobacterium Bovis BCG As an HIV Vaccine Vector

Overview

Journal Curr HIV Res

Publisher Bentham Science Publishers

Date 2010 Apr 1

PMID 20353397

Citations 21

Authors

Rosamund Chapman

Gerald Chege

Enid Shephard

Helen Stutz

Anna-Lise Williamson

Affiliations

Soon will be listed here.

Abstract

HIV-1 has resulted in a devastating AIDS pandemic. An effective HIV/AIDS vaccine that can be used to either, prevent HIV infection, control infection or prevent progression of the disease to AIDS is needed. In this review we discuss the use of Mycobacterium bovis BCG, the tuberculosis vaccine, as a vaccine vector for an HIV vaccine. Numerous features make BCG an attractive vehicle to deliver HIV antigens. It has a good safety profile, elicits long-lasting cellular immune responses and in addition manufacturing costs are affordable, a necessary consideration for developing countries. In this review we discuss the numerous factors that influence generation of a genetically stable recombinant BCG vaccine for HIV.

Citing Articles

A cell-free fluorescence biosensor based on allosteric transcription factor NalC for detection of pentachlorophenol.

Chen S, Zhao C, Kang X, Zhang X, Xue B, Li C Biotechnol Lett. 2024; 46(5):725-737.

PMID: 39017763 DOI: 10.1007/s10529-024-03511-1.

Engineering a dual vaccine against COVID-19 and tuberculosis.

Guthrie C, Tan X, Meeker A, Self A, Liu L, Cheng Y Front Cell Infect Microbiol. 2023; 13:1273019.

PMID: 37965265 PMC: 10641007. DOI: 10.3389/fcimb.2023.1273019.

Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice.

Saubi N, Kilpelainen A, Eto Y, Chen C, Olvera A, Hanke T Vaccines (Basel). 2020; 8(4).

PMID: 33202884 PMC: 7712201. DOI: 10.3390/vaccines8040678.

Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Kilpelainen A, Saubi N, Guitart N, Olvera A, Hanke T, Brander C Vaccines (Basel). 2019; 7(3).

PMID: 31382453 PMC: 6789536. DOI: 10.3390/vaccines7030078.

Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Kilpelainen A, Saubi N, Guitart N, Moyo N, Wee E, Ravi K Front Immunol. 2019; 10:923.

PMID: 31156614 PMC: 6530512. DOI: 10.3389/fimmu.2019.00923.

References

Chujoh Y, Matsuo K, Yoshizaki H, Nakasatomi T, Someya K, Okamoto Y . Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine. Vaccine. 2001; 20(5-6):797-804. DOI: 10.1016/s0264-410x(01)00398-x. View

Horwitz M, Harth G, Dillon B, Maslesa-Galic S . Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine. 2008; 27(3):441-5. PMC: 2657049. DOI: 10.1016/j.vaccine.2008.10.058. View

Hiroi T, Goto H, Someya K, Yanagita M, Honda M, Yamanaka N . HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol. 2001; 167(10):5862-7. DOI: 10.4049/jimmunol.167.10.5862. View

Bukau B, Horwich A . The Hsp70 and Hsp60 chaperone machines. Cell. 1998; 92(3):351-66. DOI: 10.1016/s0092-8674(00)80928-9. View

Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Eddine A . Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest. 2005; 115(9):2472-9. PMC: 1187936. DOI: 10.1172/JCI24617. View

Champlin R, Hunter R . Studies on the composition of adjuvants which selectively enhance delayed-type hypersensitivity to lipid conjugated protein antigens. J Immunol. 1975; 114(1 Pt 1):76-80. View

Porcelli S, Morita C, Brenner M . CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. Nature. 1992; 360(6404):593-7. DOI: 10.1038/360593a0. View

Benevolo-de-Andrade T, Monteiro-Maia R, Cosgrove C, Castello-Branco L . BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis--review. Mem Inst Oswaldo Cruz. 2005; 100(5):459-65. DOI: 10.1590/s0074-02762005000500002. View

Snapper S, Lugosi L, Jekkel A, Melton R, Kieser T, Bloom B . Lysogeny and transformation in mycobacteria: stable expression of foreign genes. Proc Natl Acad Sci U S A. 1988; 85(18):6987-91. PMC: 282104. DOI: 10.1073/pnas.85.18.6987. View

10.

Matthews P, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C . Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol. 2008; 82(17):8548-59. PMC: 2519667. DOI: 10.1128/JVI.00580-08. View

11.

Yasutomi Y, Koenig S, Woods R, Madsen J, Wassef N, Alving C . A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol. 1995; 69(4):2279-84. PMC: 188898. DOI: 10.1128/JVI.69.4.2279-2284.1995. View

12.

Constant P, Davodeau F, Peyrat M, Poquet Y, Puzo G, Bonneville M . Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science. 1994; 264(5156):267-70. DOI: 10.1126/science.8146660. View

13.

Hanson M, Lapcevich C, Haun S . Progress on development of the live BCG recombinant vaccine vehicle for combined vaccine delivery. Ann N Y Acad Sci. 1995; 754:214-21. DOI: 10.1111/j.1749-6632.1995.tb44453.x. View

14.

Genesca M, Skinner P, Bost K, Lu D, Wang Y, Rourke T . Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol. 2008; 1(3):219-28. PMC: 3401012. DOI: 10.1038/mi.2008.6. View

15.

Diniz L, Zandonade E, Dietze R, Pereira F, Ribeiro-Rodrigues R . Short report: do intestinal nematodes increase the risk for multibacillary leprosy?. Am J Trop Med Hyg. 2002; 65(6):852-4. DOI: 10.4269/ajtmh.2001.65.852. View

16.

Kawahara M . Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN gamma response, even at three years after immunization. Clin Immunol. 2008; 129(3):492-8. DOI: 10.1016/j.clim.2008.08.019. View

17.

Crampin A, Glynn J, Fine P . What has Karonga taught us? Tuberculosis studied over three decades. Int J Tuberc Lung Dis. 2009; 13(2):153-64. PMC: 3272402. View

18.

Belyakov I, Berzofsky J . Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity. 2004; 20(3):247-53. DOI: 10.1016/s1074-7613(04)00053-6. View

19.

Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S . Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol. 2005; 79(20):12871-9. PMC: 1235843. DOI: 10.1128/JVI.79.20.12871-12879.2005. View

20.

Ajdary S, Dobakhti F, Taghikhani M, Riazi-Rad F, Rafiei S, Rafiee-Tehrani M . Oral administration of BCG encapsulated in alginate microspheres induces strong Th1 response in BALB/c mice. Vaccine. 2007; 25(23):4595-601. DOI: 10.1016/j.vaccine.2007.03.039. View